Anfeng Guo
Chief Innovation OfficerMr. Anfeng Guo serves as Chief Innovation Officer of 111, Inc. since May 1, 2020. He is a former Vice President of Oncology Business Unit at Bristol Myers Squibb. He also manages Hanhong Pharmaceutical Co., Ltd., a wholly owned subsidiary of 111. Mr. Anfeng Guo is a veteran in China's pharmaceutical market for many years and worked in multinational pharmaceuticals including Pfizer, Bayer, AstraZeneca and Bristol Myers Squibb, across various fields such as sales, marketing, ecological chain construction, etc. Prior to joining 111, he was the Vice President of both Oncology Business Unit and Virology Business Unit at Bristol Myers Squibb. Mr. Guo graduated from Nanjing Tech University in 2000 and received his bachelor's degree in bio-pharmaceuticals. He received his EMBA degree in international healthcare from Nanjing University in 2018.
Positions
- Company Name111, Inc.Stock CodeYIPositionChief Innovation Officer
